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Diet is a foundation of treatment for lifestyle-related diseases, such as high blood
pressure, diabetes, and dyslipidemia. For these diseases, diet therapy has been
disregarded in management of hyperlipidemia. Fat has more diversity of biological
effects compared to those of protein and carbohydrate. New emerging evidences
have resulted in a clear shift of recognition of fatty acids in diet therapy. The
PREDIMED study has shown recently the amazing result that a calorie-unlimited,
high-fat Mediterranean diet caused about 30% reduction in cardiovascular disease
in obese subjects compared with a low-fat diet. Many authorities have removed
restriction of intake of fat from their guidelines. The important, new message from
recent medical and nutritional science is that people need to consume more “good
fat” rather than limiting intake of fat to prevent cardiometabolic diseases. In this
chapter, I would like to focus on the role of fatty acids with special relation on their
effects on blood lipids and cardiovascular events.
Keywords: saturated fat, unsaturated fat, complex and refined carbohydrate,
Mediterranean diet, olive oil, n-3 fish oil, primary and secondary prevention, LDL
cholesterol, antioxidant, diet guidelines
1. Introduction
Diet therapy has been disregarded in management of hyperlipidemia. Statistical
data for the US between 1990 and 2016 show that in addition to tobacco consump-
tion, poor diet and subsequent obesity are one of the major reasons for mortality
[1]. Generally, information about the benefits of nutritional interventions has not
adequately been translated into action in medical training or practice [2]. In a 2017
online survey of 646 cardiologists in the US [3], 90% reported that they had not
received adequate nutrition education to be able to counsel their patients, even
though 95% believed it was their personal responsibility to do so.
Compared with pharmacological trials, high-level evidence about diet therapy is
limited. Among the three macronutrients, data around fat have been especially
controversial. This is partially due to the more diverse roles of fat compared to
protein or carbohydrate. Fat is not only a source of energy production but also a
major component of hormones, and cell and nuclear membranes, and a carrier for
the fat-soluble vitamins. Furthermore, essential fatty acids are involved in many
physiological processes such as inflammation, cell proliferation, wound healing, and
blood coagulation. The data about diet therapy are frequently inconsistent even for
apparently solid recommendations in authorized guidelines. In this chapter, I would
1
like to focus on the role of fatty acids with special relation on their effects on blood
lipids and cardiovascular events.
2. Incidence of formal diet consultation in Japan
In Japan, formal professional dietary intervention is not so common. Generally,
registered dietitians provide recommendations for meals according to the patients’
disease conditions from medical, nutritional, and hygienic aspects. Statistical data
from the two university hospitals in Tokyo indicate that the number of dietary
referrals from physicians for patients with dyslipidemia is less than 5% of total
cases, which is in sharp contrast to those with diabetes at more than 50% [4, 5].
There are several reasons to explain the fewer consultations, including scanty data
in diet intervention trials in Japanese population, weak recognition of effectiveness
of diet therapy for dyslipidemia among physicians, and most importantly, patients
find it easier to take statins than follow diet therapy. Compared with LDL choles-
terol reduction by diet therapy, statins are more powerful, with up to 50% reduc-
tion in LDL cholesterol. Results in the PREDIMED study have clearly shown that a
Mediterranean diet enriched with extra-virgin olive oil or nuts reduced CV events
by 30% [6]. This magnitude of CV event reduction was compatible with those of
statin trials, and importantly, it was achieved with small changes in LDL choles-
terol, blood pressure, and blood glucose. The data in the PREDIMED study have
clearly shed light on distinctive features of the power of diet therapy, which affects
many aspects of not only classical risk factors but also other unknown biological
processes modulating the pathophysiology of diseases.
3. Effects of dietary components on blood lipid
Major diet factors that affect blood LDL cholesterol include calories, three major
nutrients (protein, fat, and carbohydrate), fat type, fiber, food sterol, etc. By
modifying these factors, a Mediterranean diet and DASH diet are intended to
improve cardiometabolic risk factors. These two diets ranked as top diets according
to a US News and World report in 2018. They share many aspects beneficial for
maintaining health. Especially, intake of healthy fats such as olive oil rather than
saturated fatty acids (SFA) is a mainstay in the Mediterranean diet. The basic
principle in diet is not to eat too much or too little of one component of foods, but
rather to eat good balance of foods. Trials that change a single dietary factor have an
advantage that makes them suitable to clarify the contribution of some specific
component on diet parameters. Studies to evaluate effects of SFA or salt on LDL
cholesterol or blood pressure are good examples. By contrast, the degree of efficacy
and durability are, generally, greater in trials changing the entire diet style. Thus,
this type of intervention trial, such as Mediterranean vs. typical western-style diet,
is more suitable as a hard endpoint study.
3.1 Calories and plasma lipids
Optimization of intake of total calories is a foundation of maintenance of healthy
life. Reducing food intake to induce undernutrition extends the life spans of multi-
ple species, ranging from single-celled organisms to mammals [7]. By contrast,
whether calorie restriction decreases CV events in human remains unclear except in
bariatric surgery. The LookAHEAD study examined whether an intensive lifestyle
intervention for weight loss for 10 years would decrease CV morbidity and
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mortality among 5145 obese patients with type 2 diabetes [8]. The intensive lifestyle
intervention was aimed at achieving and maintaining weight loss of at least 7% by
focusing on reduced caloric intake (calorie goal of 1200–1800 kcal per day,
restricting fat calories to <30%) and increased physical activity. Although greater
reductions in all CV risk factors was observed in the intervention group than in the
control group, the rate of CV mortality and myocardial infarction was not different
(Figure 1a). Rebound of weight in the intervention group (Figure 1b) increased the
statin use in the control group, and the lack of instruction about saturated and
unsaturated fats is suggested for reasons of the negative results in this study. Five
years later, in the PREDIMED study [6], a Mediterranean diet loaded with high
content of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids
(PUSA) without calorie restriction and exercise recommendation reduced CV
events significantly approximately by 30% compared to the control low-fat diet
group (Figure 2). It is noteworthy that the reduction of CV events occurred in the
Mediterranean diet groups that consumed about 200–250 kcal higher calories as fat
than in the control group. The data of these two studies [6, 8] have strongly
suggested that intake of unsaturated fat is more effective than a low-fat, low-calorie
diet for reduction of CV events. However, weight reduction by the low-fat diet in
the LookAHEAD study has brought in important health benefits other than CV
event reduction. Patients in the low-fat group were more likely to have a partial
remission of diabetes during the first 4 years of the trial [9], more improvement in
terms of reductions in urinary incontinence [10], sleep apnea [11], and depression
[12] and improvements in quality of life [12], physical functioning [13], and mobil-
ity [14] than were those in the control group. Calorie restriction by diet is effective
in reducing body weight in obese subjects. Therefore, diet therapy should be indi-
vidualized dependent on the treatment goal, patient’s characteristics such as under-
lying disease, BMI, and daily diet habits.
The difference in LDL cholesterol in the two groups in the LookAHEAD study
was 1 mg/dl at the end of study [8]. By contrast, the effects of bariatric surgery on
plasma LDL cholesterol and CV events have been clearer, because bariatric surgery
reduces body weight to a greater extent, 20–40% from baseline. In a study of
registry data in Sweden, LDL cholesterol was reduced approximately 40% associ-
ated with a 30% decrease in all-cause mortality 15 years after the surgery [15].
Figure 1.
(a) Kaplan-Meier curves of the primary end point in look AHEAD study [8]. The primary outcome was a
composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or
hospitalization for angina. (b) Changes in body weight in the look AHEAD study [8].
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Bariatric surgery has also resulted in the remission of concomitant risk factors. A US
cohort study in 2458 obese subjects showed that after gastric bypass surgery, the
remission rate of was 62% for dyslipidemia, 38% for hypertension, and 68% for
diabetes [16]. More than 150,000 bariatric surgeries had been performed in the US
in 2013, which were almost one third of operations performed globally in 2013 [17].
Data from the bariatric surgery clearly indicate that it is important to provide
substantial and sustainable body weight reduction for obese subjects in order to
decrease CV events. If patients have difficulty maintaining calorie restriction,
emerging evidence has been accumulating that a calorie-unlimited but
well-balanced diet with MUFA/PUFA is a good choice.
3.2 Data and issues of low-carbohydrate vs. low-fat diet
In order to prevent muscle and bone wasting in aged people with sarcopenia,
many scientific guidelines recommend that protein intake should be at least 1 g/kg/
day of standard body weight unless renal function is abnormal. Thus, in limiting
dietary calories, the requirement for protein usually cannot be changed. Much
controversial data have been reported regarding whether the restriction of carbo-
hydrate or fat is better in subjects with obesity or diabetes. Reduced carbohydrate
diets are defined as having carbohydrate intake below the Dietary Guidelines for
Americans (DGA) recommendation (45–65% of total energy intake). Regarding
effects on body weight, several previous systematic reviews and meta-analyses
[18–20] have shown that low-carbohydrate high-fat diets are just as effective, if not
more so, than low-fat high-carbohydrate diets. Excess energy from carbohydrates
stimulates the induction of lipogenesis in the liver via SREBP-1, resulting in
accumulation of triglycerides (TG) in many organs [21], which induces obesity,
Figure 2.
Kaplan-Meier curves of the primary end point in the PREDIMED study [6]. The primary end point is a
composite of acute myocardial infarction, stroke, and death from cardiovascular causes.
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dyslipidemia, and insulin resistance. Thus, the restriction of carbohydrates results
in not only weight reduction but also improvement of dyslipidemia and insulin
resistance.
Evidence has shown that under the controlled condition, both of the total calorie
and the type of carbohydrate can affect body weight positively or negatively and
plasma lipid profile as well. Even when receiving a high-calorie diet with increased
fat content, obese subjects (BMI > 30) could reduce more weight with a low refined
carbohydrate diet, compared with high-refined carbohydrate, low-fat, and energy-
restricted diets in 1 year, based on a meta-analysis [22] and a 2-year intervention
study [23]. One general consensus is that because refined carbohydrates are associ-
ated with high glycemic index, limiting intake of refined carbohydrates improves
postprandial hyperglycemia, resulting in lower insulin release as well as decrease in
body weight. In the period 1980–1990, calorie restriction by eating low-fat food was
strongly recommended in many places in the US. The big issue of this nation-wide
trend of low-fat diet was that most people were eating food containing refined
carbohydrates with high glycemic index instead of fatty food (Figure 3a). An
obesity epidemic in this period in the US coincided with the low-fat campaign.
During the epidemic, the rate of obesity was almost triple, and the rate of diabetes
doubled compared with three decades earlier [24, 25] (Figure 3b). It is ironic that
people lost more money (low-fat food was generally more expensive) and gained
weight while eating a low-fat diet.
In the OmniHeart study [26], the recommendation of fructose-sweetened bev-
erages defined in the protocol could be one reason why the high-carbohydrate diets
group showed the worst cardiometablic effects. Because of recent data showing
fructose has worse effects on cardiometabolic risk markers than any other carbohy-
drates, the conclusion from the OmniHeart study cannot be extrapolated to all
carbohydrates. Beverage makers in the US used to actively campaign by insisting
that “over calories” was the reason for obesity rather than the type of sweetened
carbohydrates included in beverages. However, each mono- and disaccharide has
different effects on body metabolism. In a feeding study in overweight subjects,
comparison of drinking glucose- or fructose-sweetened beverages for 10 weeks
showed that after fructose intake, fasting plasma glucose, insulin levels, and visceral
adipose volume increased with a decrease in insulin sensitivity compared with the
intake of glucose-sweetened beverages [27]. Glucose metabolism in blood and liver
is tightly regulated by insulin and glucagon. On the other hand, because
fructokinase does not play any role in the regulation of accumulation of fructose in
the liver, the concentration of fructose in blood and liver increases with oral intake
of fructose, which is called unregulated fructose uptake [28, 29]. Consequently,
Figure 3.
(a) Changes in average fat and carbohydrate caloric consumption in adults from 1965 to 2011 [25].
(b) Changes in average BMI in adults from 1965 to 2011 [25].
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accumulated fructose in the liver stimulates de novo lipogenesis and results in
detrimental effects on glucose and lipoprotein metabolism [27].
Because of few reliable RCT, there have been many controversial results when
comparing beneficial effects between low-fat and low-carbohydrate diet. It appears
that the type of macronutrients replaced for fat or carbohydrate has significant
effects on those results. A recent meta-analysis of studies with 432,179 subjects has
shown that participants in low (<40%) and high (>70%) carbohydrate consump-
tion groups had greater mortality than in moderate consumption groups, which is
consistent with a U-shaped association [30]. The results varied according to the
source of macronutrients. Namely, the mortality increased when carbohydrate was
replaced with animal-derived fat or protein, and the mortality decreased when the
substitutions were plant-based. This indicates that food source can be an important
consideration for CV outcomes when one macronutrient is replaced with another
macronutrient. It has been hypothesized that diets of lower plant carbohydrate with
increased animal protein and fat stimulate inflammation, aging, and oxidative
stress. On the contrary, nutrition based on low-carbohydrate and high-fat diet may
have anti-inflammatory, anti-oxidative, and anticancer effects. A diet that contains
reduced carbohydrate with higher fat or even a ketogenic diet, very low carbohy-
drate diet (<10% of carbohydrate calorie), slows down cancer growth and prolif-
eration [31, 32]. Before instructing a patient to follow a low-fat or low-carbohydrate
diet, clinical factors should be considered, including age, body weight, diet habits,
underlying diseases, and kidney function. For example, a 75 y/o obese subject with
diabetes who consumes a high-calorie diet with high content of fat from animal
origin should decrease animal fat intake to reduce total calories for control of body
weight. It makes sense to replace animal-fat with complex carbohydrates rather
than plant-based unsaturated fat. This way would protect against the increase in
total calories and let the glucose level decrease. If a subject has a history of myocar-
dial infarction, partial substitution of animal fats with MUFA, such as found in olive
oil, is another option, because of protection of CV disease by intake of olive oil. By
considering many aspects of benefit and harm of carbohydrates and fat in this way,
appropriate dietary composition should be individually fine-tuned based on
patients’ clinical characteristics and treatment goals.
3.3 Comparison of guidelines in Japan, the US, and Europe regarding fat
content
Table 1 summarizes comparison of recommendations about dietary fat in
several key scientific societies in the US, Europe, and Japan. Calorie intake from
fat is restricted to 20–30% in guidelines of Ministry of Health, Labour and
Welfare (MHLW) of Japan [33], Japanese Diabetes Societies (JDS) [34], and
Atherosclerosis Societies (JAS) [35]. This value of 30% is classified as low-fat diet as
defined by the 2014 the American Diabetes Association (ADA) guideline [36].
There are several reasons why restriction of calories from fat still remains in these
recommendations in Japan. First, the LDL cholesterol level in Japanese is steadily
increasing recently and at present it is higher among Japanese females than in
American females [37]. A high-fat diet generally increases intake of SFA, resulting
in increases in LDL cholesterol. Second, BMI in Japanese people is lower than in
Caucasians. It is well known that thin Asian people are prone to develop diabetes
with a mild increase in body weight. Therefore, because increases in fat calories are
usually associated with increases in total calories and subsequently in body weight,
restricting fat calories is often helpful to prevent worsening in blood glucose in
diabetic subjects.
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By contrast, in of the 2014 ADA guideline [36], lifestyle management by Amer-
ican Heart Association (AHA)/the American College of Cardiology (ACC, 2013)
[38], European Society of Cardiology (ESC)/European Atherosclerosis Society
(EAS, 2016) [39], and the Dietary Guidelines for Americans 2015–2020 [40], the
upper limit in fat calories has been actually dropped, and they describe that it is
advisable to determine it on an individual basis along with maintaining whole
calories. Each of these guidelines stresses quality of fat rather than the total quantity
of fat intake. There are a few important considerations for this major change. First,
many people tend to often eat more refined carbohydrates as replacement for fat,
and previous data have not shown clearly that this would reduce CV mortality and
motility. A high-fat diet reduces body weight more than a high-refined carbohy-
drate diet [22, 23], which favors abandoning the upper limit of total fat intake from
many guidelines. Second, limiting overall fat intake habitually carries the potential
risk of reducing consumption of “good fat” such as MUFA/PUFA [36, 38–40]. All
the guidelines have quoted data in the PREDIMED study, where a calorie-
unlimited, fat-unrestricted Mediterranean diet reduced CV events about 30% com-
pared with a low-fat diet [6]. It is noteworthy that fat calories in the Mediterranean
intervention group was exceeded 40% in the PREDIMED study. The important
message in removing the upper limit for fat calories from these guidelines is that to
maintain consumption of an appropriate level of calories, one must include healthy
















Total fat 20–25% N/Aa N/Rb 20–30% N/Rc 25–35% N/R
MUFA N/Ad N/Ad N/A N/A N/Ae <10% N/Ad
PUFA N/Ad N/Ad <10%e N/A N/A <20% N/Ad












SFA 4.5–7% <5–6% <7% <7% <10% <7% <10%
Trans fat <1% ↓i <1% ↓i ↓i <1% ↓i
Cholesterol <200 mg N/Aj <300 mg <300 mg <300 mg <200 mg N/Aj
N/A: not available; N/R: no restriction; MUFA: monounsaturated fatty acids; and PUFA: polyunsaturated fatty
acids.
aRecommendation for Mediterranean diet which usually has 32–35% as fat calorie.
bNo restriction of fat intake, which is dependent upon individual preferences. However, fat intakes at >35% of calories
are generally associated with increased intakes of both saturated fat and calories.
cNo restriction of fat intake, inconclusive for an ideal amount of total fat intake for people with diabetes; therefore,
goals should be individualized. Fat quality appears to be far more important than quantity.
dNot stated on intake of mono- and polyunsaturated fat. However, there are comments of improvement of LDL
cholesterol by substitution of SFA with MUSA or PUFA.
eIntake of n-6 PUFAs should be limited to 10% of the energy intake in order to minimize the risk of lipid peroxidation
of plasma lipoproteins and to avoid any clinically relevant HDL-C decrease.
fRecommend intake of fish. Increase in n-3 fat decreases plasma TG level with potential beneficial effects on CV events.
gRecommend intake of fish. Increase in n-3 fat decreases plasma TG level. Unknown for reduction of CV events.
hRecommend intake of fish. However, increase n-3 fat has no effects on prevention of diabetes and on CV events in
diabetes.
iNo upper limit defined. However, should decrease as much as possible.
jNo upper limit.
Table 1.
Recommendations for intake of fat and cholesterol-related nutrients in major guidelines.
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3.4 Issues and limitations around nutritional trials
There have been several limitations of studies in nutritional science. Usually, a
nutritional study lacks a double-blind design and a placebo for food. Without a
placebo-controlled design, the study can provide no true evidence of either benefit
or harm of the intervention. For example, if SFA were replaced by carbohydrate or
protein, the isolated effect of SFA would be influenced by the changes in the
composition of the other macronutrients to keep the diet calorie constant, which
would make the isolated effect of SFA difficult to evaluate. Even in the subcate-
gories of SFA, MUFA, and n-3, n-6 PUFA, there exists clear heterogeneity within
each group that contributes to different biological effects. Furthermore, the food
content within its SFA can have a significant impact on CV risk. The fermentation
of dairy products provides a good example. The content of SFA in cheese is very
high (20 g in 100 g of natural cheese compared with 3 g in 100 g of beef sirloin). A
10-year cohort study showed that the consumption of SFA from dairy products was
associated with decreased risk of CV disease, and, by contrast, a higher intake of
SFA from meat (including red and processed meat and poultry) was associated with
greater CV disease risk [41].
Under- and over-reporting of dietary intake is common in nutritional studies. In
contrast to easily countable items like coffee and sweetened beverages, the per-
centages of energy from fat and added sugar based on a food frequency question-
naire (FFQ) were underestimated [42]. Regarding longevity of habits of food
intake, the protocol design in one cohort study had a diet assessment at baseline and
approximately 36,000 participants were followed for 12 years [43]. This is a com-
mon type of study, in which a one time-point assessment can predict the occurrence
of disease many years later.
The logic behind limiting the intake of SFA is derived from the risk factor model
for coronary heart disease (CHD) causality, in which LDL cholesterol is a causal
factor for CHD and a diet including SFA increases LDL cholesterol compared with
other macronutrients. However, other biomarkers that predict CHD risk more have
been proposed such as total cholesterol to HDL cholesterol ratio, small dense LDL
cholesterol, apolipoprotein B, and others. Therefore, total CHD risk may be
increased with elevations of these biomarkers even if LDL cholesterol does not
change after the diet intervention.
Evidence coming from RCT is generally positioned above evidence from cohort
studies in the research hierarchy. Findings in diet- and health-related RCTs are not
necessarily more reliable than those from well-conducted cohort studies [44]. RCTs
sometimes include subjects with underlying diseases and follow them up with a
relatively short period. This means substantial limitation to extrapolate findings
from RCTs to healthy persons, when CV events occur rarely over many years.
Cohort studies also have their own sources of error, especially issues of confounding
factors. For example, SFA intake is associated with behaviors indicating lower
health consciousness, [45] whereas PUFA intake is either associated with behaviors
indicating greater health consciousness [46], or is not related to health conscious-
ness [47]. Therefore, confounding variables also often explain the inconsistent
results regarding the replacement of SFA with PUFA for prevention of coronary
heart disease. When reading manuscripts in nutritional studies, one must keep in
mind these limitations and issues included in the studies.
3.5 Effects of replacement of SFA with PUFA
A high-SFA diet is quite palatable with weak effect on satiation, which results in
potentially overconsumption and obesity [48]. There has been a tremendous amount
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of data showing that reducing SFA in food resulted in health benefit by lowering
blood LDL cholesterol and CV events in RCT [49, 50], prospective cohort studies
[51–53], and epidemiological studies [54]. Based on this evidence, AHA has
recommended to decrease over-consumption of SFA since 1961. On the other hand,
one RCT [55], a prospective cohort study [43], and meta-analysis [56] have reported
that increases in SFA are not associated with increases in CV events. In the US where
both myocardial infarction and consumption of beef are more than triple than that in
Japan, whether the consumption of SFA in food results in health problems should be a
serious issue [57, 58]. One recent article in the Annals of Internal Medicine in 2019 has
concluded that red meat may have little or no effect on CV outcomes and cancer
mortality based on low- to very-low-certainty evidence [59]. Just after this publica-
tion, roughly 2000 emails, mostly caustic in tone, were sent to the inbox of an editor
in the journal as a wave of backlash, including a push from one group attempting to
have the guideline retracted even prior to publication.
The message from guidelines in major scientific societies reaches the same con-
clusion that limiting intake of SFA by replacing with MUFA and PUFA reduces LDL
cholesterol and potentially reduces CV diseases. This conclusion was summarized in
a position paper by the 2017 AHA presidential advisory board [60], which relied on
four core randomized trials [61–64]. Results of a meta-analysis of these four core
trials [60] are shown in Figure 4. The results showed that lowering calorie from
SFA down to 7% and replacing them with vegetable oil rich in PUFA, primarily
soybean oil, lowered blood cholesterol by 15% and the incidence of coronary heart
disease (CHD) by 29%. The degree of efficacy by cutting this amount of SFA is
compatible with that of statins [65].
Although it has become now widely accepted that the dominant dietary factor
involving coronary heart disease is an excessive intake of SFA, recent new evidence
has suggested that SFA may play a much less important role in coronary heart
disease than was previously believed. As discussed previously, potential biases have
been often included in diet studies, and earlier meta-analyses did not sufficiently
account for major confounding variables. One study has shown different results in
two meta-analyses of collecting only adequately controlled trials from collecting
only inadequately controlled trials (Figure 5) [66]. These data clearly represent one
typical example of difficulty in conducting well-controlled diet trials. The manu-
script of the 2017 AHA presidential advisory board [60] that selected the 4 core
RCTs may have had potential bias by excluding or including some studies from the
Figure 4.
Meta-analysis of core trials on replacing saturated with polyunsaturated fat [60].
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analysis. Notwithstanding apparently consistency of the description in many
authoritative guidelines of harmful effects of SFA, some experts are insisting that
there have been no solid evidence indicating that the consumption of SFA is related
with higher incidence of CV disease [67].
It seems that one common key message in studies that the overestimated harm-
ful effects of SFA is that other factors (e.g., increased refined carbohydrate/added
sugar included in soft drinks, or trans fat; or decreased fish, fruit, and vegetables)
play a more role in development of coronary heart disease than SFA [68]. However,
previous data of substitution of SFA with PUFA have consistently shown improved
blood lipid profile and blood pressure. Furthermore, increased intake of SFA from
animal meat and butter generally is accompanied by more consumption of trans fat
or other substances with potentially harmful effects on humans. The Mediterranean
and DASH diets, which include high amount of MUFA and PUFA with low contents
of SFA, have constantly shown health benefits. Based on all these data, as in the
authorized opinions, restriction of SFA is a reasonable strategy.
3.6 Effects of replacement of SFA with MUFA
Compared with PUFA, less data have been available evaluating benefits of
MUFA [69]. In human cohort studies, the replacement of SFA with MUFA yielded
smaller reduction of LDL cholesterol [70] and incidence of CHD [71–73], compared
with PUFA. One huge cohort study in 127,536 subjects combining the Nurses’
Health Study and the Health Professionals Follow-up Study has shown that
replacing 5% of energy intake from SFAs with equivalent energy intake from PUFA
or MUFA was associated with a 25 and 15% lower risk of CHD, respectively
(Figure 6) [73]. A review of the Cochran database in 2015 has concluded that
replacing the energy from SFA with PUFA appears to be a useful strategy and that,
by contrast, effects of replacement with MUFA were unclear due to inclusion of
only one small trial [69].
Figure 5.
Forest plot showing pooled RR with 95% CI for the number of total CHD events [66].
10
New Insights into Metabolic Syndrome
The source and origin of MUFA within a specific diet may explain the inconsis-
tent previous results with MUFA [74]. One huge meta-analysis including 32 cohort
studies in 840,000 subjects has shown data that effects of MUFA on CV disease and
its mortality varied depending on the different dietary sources of MUFA. Whereas
MUFA of mixed animal and vegetable sources per se did not yield any significant
effects on major CV outcomes, importantly, significant associations could only be
found between higher intake of olive oil and reduced risk of CV events. It is of note
that all studies which showed benefit for CV risk were conducted in the Mediterra-
nean nations where extra-virgin olive oil is the most dominant source of this type of
fatty acid [75]. The amounts of olive oil in the highest consumption group used in
those studies were > 30 g/day in the EPIC cohort (in Spain), 48 g/day in the EPIC
cohort in Greece [76], 52 g/day in a case-controlled study in Spain [77], and 56 g/day
in the PREDIMED study [78]. Although mean olive oil consumption in the US is
increasing, it is still very low at 4.2 g/day in 2010 compared with those in the
Mediterranean areas (Figure 7) [79]. Another study in Spain has shown clearly
different effects on cardiometabolic parameters between olive oil and sunflower oil
(11% for MUFA and 60% for PUFA) [80]. With a slight increase in LDL cholesterol
in the olive oil group, olive oil improved other risk factors such as glucose, TG,
and body weight to a greater extent than in the sunflower oil group. The amount of
olive oil in this study was expected to be more than 40 g/day, based on data showing
that Spanish diet usually includes olive oil accounting for 18% of calorie intake [81].
All of these findings indicate that a large amount of olive oil (probably > 30 g/day)
has distinctive effects compared with other oils from plant or animal origin.
Along with firm evidence of CV event reduction in two RCTs (Lyon Diet Heart
study [82, 83] and PREDIMED [6]), olive oil should be viewed not only as “better”
MUFA but also as a nutrient including many biologically active ingredients such as
polyphenol. In 2018, the FDA approved a qualified health claim for consuming oils
with high levels of oleic acid (major MUFA in olive oils) to reduce risk for coronary
heart disease [84]. This new claim allows manufactures of olive oils to state that
“supportive but not conclusive scientific evidence” suggest that daily consumption
of one and half tablespoon (20 g) of olive oil may reduce CHD risk.
Figure 6.
Estimated percent change in the risk of CHD after isocaloric substitute of SFA (upper half) or refined
carbohydrate (lower half) by other nutrients [73].
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3.7 Effects of replacement of saturated fat with carbohydrate
In many studies which replaced SFA with carbohydrate, total calories from fat
was roughly reduced from 40% to 20–30%, and this has affected diet adherence in
subjects who are accustomed to eating oily food. In the Women’s Health Initiative
Study [85], the protocol intended originally to reduce fat calories from 37 to 20% in
the low-fat/high carbohydrate group. In 8 years, the fat calories increased to 37% in
this group, which was higher than the fat calories in the control group (35%)
because of poor compliance. In the low-fat/high carbohydrate group, although LDL
cholesterol decreased by 3 md/dl, CV events were not reduced significantly. One
meta-analysis including 15 randomized controlled trials with 59,000 participants
[69] concluded that the replacement of SFA with carbohydrates reduced LDL
cholesterol mildly (5%) without affecting CV events. In most of the studies used in
this meta-analysis, it is noteworthy that refined carbohydrates were incorporated as
replacement for SFA. A growing weight of authoritative opinion is to recommend
intake of complex carbohydrates including much fiber and minerals. Two recent
studies [56, 86] have also shown the same results that the CV benefit by reduced
SFA tends to be neutralized by increasing intake of refined carbohydrates.
Combined analysis of two prospective, cohort studies [73] in the Nurses’ Health
Study (84,628 women) and the Health Professionals Follow-up Study (42,908 men)
has the advantage of investigating effects of different sources of carbohydrates,
refined or complex, on CHD risk for long periods up to 30 years. Figure 6 shows
that when 5% of energy from SFA was replaced with 5% of energy from carbohy-
drates, the risk of CHD decreased by 9%. By contrast, when replaced with refined
carbohydrates/added sugars, the risk of CHD did not decrease. This study has also
shown change of CHD risk when refined carbohydrates/added sugars were replaced
with other nutrients. Replacing refined carbohydrates/added sugars with MUFA,
PUFA, or complex carbohydrates was significantly associated with a lower risk of
CHD (5, 21, and 12%, respectively). However, there was no change in the risk of
CHD when refined carbohydrates/added sugars were replaced with SFA. Results of
this cohort study provide additional evidence that effects of refined carbohydrates
on CV risk are at least equipotent to those of SFA.
Figure 7.
Trends of types of fat intake from 1990 to 2010 in Nurses’ Health Study (NHS) [79].
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At present, intact or minimally processed carbohydrates where fiber, bran,
and germ content is high are generally called complex carbohydrates. Bran of
whole grain is fiber-filled outer layer with many vitamins and minerals, and
germ, which is a nutrient-packed core, includes phytochemicals, unsaturated fat as
well as vitamins. Differences in complex and refined (simple) carbohydrates are
shown in Table 2. The mechanisms for harmful cardiometabolic effects of refined
carbohydrates are mostly explained by their ability to increase insulin release and
shorten satiety [87]. Refined carbohydrate also do not have as much vitamins and
fibers as complex carbohydrates. A diet with refined carbohydrates with high
glycemic index such as rice is associated with higher incidence of coronary heart
disease and diabetes [88–91]. Reduction of refined carbohydrates in food has
decreased blood pressure, TG, and high-sensitivity CRP, and improved insulin
resistance [92, 93].
Emerging evidence regarding the harmful effects of SFA and refined carbohy-
drates on cardiometabolic markers has exerted significant effects on the food label
authorized by FDA. Some experts have opinion to recommend on leaving percent
daily value of SFA with dropping % total fat, and adding on % refined carbohydrate
instead of % carbohydrate against the daily value of these nutrients [94]. Because of
data showing that refined carbohydrates with high glycemic indices worsen diabetic
status, the FDA changed the nutrition facts section of the food label in 2019 to
require listing the amount of and percent daily value for added sugars (Figure 8,
arrow 1). Furthermore, “Calories from Fat” was removed, because abundant data
show that the type of fat is more important than the amount (Figure 8, arrow 2).
Foods and drinks that contain no significant nutrients but are high in calories are
said to have “empty calories.” Drinks with added sugar are a typical example of
empty calories. Sugar-sweetened beverages are the largest source of added sugar in
the diet. In the US, the consumption of sugar-sweetened beverages has decreased
modestly since around 2009; however, the intake level is still high (Figure 9) [95].
The Dietary Guidelines for Americans [40] and WHO [96] recommend no more
than 10% of daily calories from all added sugars. As shown in Figure 9, adults in the
US consumed an average of 160 kcal/day from sugar-sweetened beverages in 2014.
This means that sugar-sweetened beverages alone correspond to 8% of total calo-
ries. To date, a large body of evidence supports a strong link between intake of
sugar-sweetened beverages and weight gain [97], risk of type 2 diabetes [98], and
CV diseases [99–101]. Sugar-sweetened beverages, as well as saturated fat, present a
clear target for health policy.
Complex Simple (or refined)
Structure Polysaccharides Mono, disaccharides
Taste No taste Sweet
Digestion Slow Easy
Blood sugar Slowly increases Rapidly increases
Insulin response Low High
Glycemic index Low High
Satiety Longer Shorter
Fiber High Low
Body weight Loss Gain
Table 2.
Differences in two types of carbohydrate: complex vs. simple (refined).
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3.8 Effects of replacement of SFA with other nutrients on plasma lipids, blood
pressure, and other risk markers
Replacing 1% of energy from SFA with 1% of energy from PUFA, MUFA, or
complex carbohydrates decreased plasma LDL cholesterol by 2.1, 1.6, and 1.3 mg/dl,
respectively [102]. HDL cholesterol decreased by 0.2, 0.2, and 0.4 mg/dl after
substitution of SFA by PUFA, MUFA, or complex carbohydrate. The change in TG
Figure 8.
Changes in the format of the nutrition label of the original and the new version on Jan 2020.
Figure 9.
Sales of sugar-sweetened beverages (SSBs) in kcal/person/day by beverage type in 2009–2014 in some selected
countries [95].
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was 0.9, 0.4, and +1 mg/dl by substituting with PUFA, MUFA, or complex
carbohydrates. These data indicate that in order to decrease LDL cholesterol or TG,
the best strategy is to reduce the intake of SFA. SFA exert different LDL increasing
ability depending on chain length. However, this difference is not clinically so
important, because every oil contains several SFAs with various chain lengths. In
general, there are progressive increases in LDL-C with diminishing chain length.
The potency of the LDL-raising effects of individual SFAs is lauric acid
(C12:0) > myristic acid (C14:0) > palmitic acid (C16:0) [103].
SFA may affect the risk of CV disease independently of LDL cholesterol, through
the effects on inflammation, endothelial function, thrombosis, and ventricular
arrhythmias [104]. One ex vivo randomized cross-over study showed that a break-
fast with butter (35% SFA) induced a higher increase in TNF-alfa mRNA than
breakfasts with olive oil (36% MUFA) or walnuts (16% PUFA), and also a higher
response in IL-6 mRNA than the walnut breakfast in peripheral blood mononuclear
cells (PBMCs) in healthy subjects (Figure 10) [105]. In another study, LDL-induced
adhesion of monocyte to endothelial cells was also lower after MUFA consumption
than after SFA in healthy individuals [106]. Some other ex vivo studies in humans
have shown that consumption of butter was associated with more activated genes
involved in the regulation of cell proliferation and inflammation compared with
consumption of olive oil or vegetable oil [107, 108]. In these studies, activation of
inflammatory markers has occurred without significant changes in the blood lipid
profile [106, 108]. In summary, the previous findings strongly suggest that satu-
rated and unsaturated fats have unique biological effects on vascular walls which
are independent on the reduction in LDL cholesterol, which is like the effects of
statins.
3.9 Guideline recommendations for dietary intake of SFA
Guidelines of authoritative opinions in Japan, the US, and Europe including
cardiology, diabetes, and atherosclerosis societies except ADA [36] recommend less
than 7% of calorie from SFA in subjects with background diseases (Table 1). In
healthy subjects, the recommended upper limit of SFA is 7% in Japan [33] and 10%
in the US [109]. Restriction of SFA to <10% rather than 7% in diabetic subjects as
recommended by the ADA [36] may sound a little strange, because diabetes is
associated with high CV risk, and on-target LDL cholesterol criteria is generally
more stringent. This recommendation is based on the data from one small 3-week
study that compared a low SFA diet (8% of total calories) vs. a high SFA diet (17%
of total calories), and showed no significant difference in glycemic control and most
CVD risk measures [110]. Therefore, there is limited research regarding effects of
Figure 10.
Response of mRNA TNFα (left) and IL-6 (right) in breakfast with butter, olive oil, and walnuts measured in
peripheral blood mononuclear cells (PBMCs) [105].
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SFA on diabetic control, and the ADA nutrition position paper recommends people
with diabetes follow the guidelines for the general population, which is 10%
according to USDA [109]. Despite insufficient data about effects of SFA on glyce-
mic control, the evidence in many review manuscripts or meta-analyses so far
accumulated has indicated that a Mediterranean diet helps prevent type 2 diabetes
and causes HbA1c reduction in persons with established diabetes [111–115]. There-
fore, food habits to restrict intake of SFA as in the Mediterranean diet is a very
reasonable strategy in diabetic subjects.
Three Japanese cohort studies have shown that the incidence of brain hemor-
rhage is inversely related to intake of SFA [116–118], and this moved the JAS to
define the lower limit (4.5%) of intake of SFA [35]. This relation has not been
demonstrated in meta-analysis of subjects in the US and Europe. There have been
no data showing high incidence of stroke in vegetarians who consume very little
SFA. Therefore, none of the guidelines in the rest of the world have incorporated
the lower limit of intake of SFA. One has to be cautious that limiting SFA in the diet
tends to decrease intake of good fat, as PUFA, fish oil, or olive oil.
Intake of 7% of calories as SFA is equivalent to about 15 g of SFA in a person who
needs 2000 cal/day. Average intake of SFA is 15.2 and 13.8 g/day for Japanese men
and women at the age of 30–49 years old [119], and 31.4 and 20.3 g/day for
American men and women at the age of 31–50 years old [120]. It is reasonable that
refraining from red meat, processed meat, butter, or SFA-loaded snacks is a simple
way to cut SFA in daily food habits. In the US, only approximately 5% of the
population consumes less than 7% of their calories from saturated fat [120].
3.10 Guideline recommendations for dietary intake of PUFA and MUFA
Beneficial effects of PUFA and MUFA seem to be fully recognized in guidelines
in the US and Europe (Table 1). Guidelines from ADA, ACC/AHA, NLA, and
USDA strongly recommend the Mediterranean and DASH diets. Regarding efficacy
of decreasing blood glucose, the ADA provides the same recommendation for both
PUFA and MUFA [36]. The 2013 AHA/ACC Guideline on Lifestyle Management
[38] states that PUFA or MUFA should be used for reducing LDL cholesterol instead
of SFA at the same recommendation level.
Literature has emerged that the biological effects of olive oil differ from those of
plant-based MUFA or PUFA. Incorporating data from the PREDIMED study [6],
the 2016 Canadian Cardiovascular Society Guidelines for the Management of
Dyslipidemia [121] concretely recommend olive oil (>60 ml/day) and nuts (>30 g/
day) rather than using general terms for MUFA. An authoritative review of dietar-
ies and policies for cardiovascular diseases in 2016 [122] has also listed its daily
recommended doses of MUFA and PUFA, such as 10–30 ml/day of soybean oil
(MUFA: 22%, PUFA: 56%, and SFA: 15%), extra virgin olive oil (MUFA: 74%,
PUFA: 7%, and SFA: 13%), and canola oil (MUFA: 64%, PUFA: 28%, and SFA: 7%).
These guidelines provide data of effects on plasma LDL cholesterol and CV events
by substitution of SFA with PUFA and MUFA.
The differences in guideline recommendations of the fat intake appear to reflect
the differences in food habits and in recognition of the benefits of healthy fats
between countries. In 2010, nonoptimal intake of n-6 PUFA, SFA, and trans fat
resulted in 710,000, 251,000, and 537,000 deaths from CHD per year worldwide
[123]. In 80% of nations, including Japan, China, and other many Asian nations,
CHD burdens attributable to n-6 PUFA were 2-fold higher than the SFA-
attributable burdens. These data indicate that it is more important to focus on
increasing healthful n-6 rich vegetable oils in the diet than to focus on replacement
of SFA and carbohydrates for public health benefits.
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4. Cholesterol
4.1 Relation of plasma LDL cholesterol and dietary intake of cholesterol
Plasma LDL cholesterol value changes depending on oral intake of cholesterol.
One meta-analysis of 17 studies reported that a 100 mg increment in dietary cho-
lesterol from eggs elevated plasma total cholesterol by 2.2 mg/dl [124]. On the
contrary, many studies have brought into question the apparent association
between dietary cholesterol consumption and blood cholesterol [38]. Plasma cho-
lesterol undergoes a highly degree of regulation to balance absorption in the intes-
tine and synthesis in the liver [125]. Low dietary cholesterol intake is compensated
for by an increase in absorption. These mechanisms explain the inter-individual
variability in absorption (20–80%) in humans. Thus, there are responders and
nonresponders to intake of cholesterol in terms of plasma cholesterol levels. Inter-
estingly, repeated cholesterol loading has changed some nonresponders to
responders [126, 127]. The presence of two types of cholesterol response may reflect
just day-to-day variation of cholesterol absorption from the gut in a single person
rather than a true difference between responders and nonresponders. In
responders, both LDL and HDL cholesterol increased with no change in ratio of
LDL to HDL. A gene of ABCG5/8 regulates absorption of dietary cholesterol and
sterol from gut [128]. People carrying polymorphisms of ABCG5/8 have a higher
absorption rate of cholesterol. In these subjects, the effects of manipulation of
intake of cholesterol in food on plasma LDL cholesterol levels have been very
significant.
The possible link between dietary cholesterol and CHD risk is potentially
distorted by confounding factors from other features in the diet, especially SFA
[129]. A previous recommendation of less than 300 mg of dietary cholesterol has
been removed from the 2013 AHA/ACC Guideline on Lifestyle Management to
Reduce Cardiovascular Risk [38], stating that there is insufficient evidence to
determine whether lowering dietary cholesterol reduces LDL-C. The same action
was taken in the 2015 Dietary Guidelines of USDA [40] and the 2015 Japanese
dietary intake standards by Ministry of Health, Labor and Welfare [33]. By con-
trast, other guidelines still restrict the dietary cholesterol intake, for instance,
200 mg/day in JAS [35] and AACE [130] guidelines, or 300 mg/day in ESC/EAS
[39], ADA [36], and JDS [34] guidelines. These guidelines engender the risk of
potentially increasing intake of SFA by abandoning the recommendation for dietary
cholesterol intake. However, all of these, in common, stress risk evaluation of
atherothrombotic diseases and execution of comprehensive management to reduce
the risk. Even the guideline from JAS, which limits dietary cholesterol intake at
200 mg/day, states very clearly that only restricting dietary cholesterol intake is
hardly efficacious in reducing plasma LDL cholesterol, and rather more attention
should be paid to reducing SFA in food.
5. Polyunsaturated fat
5.1 n-3 and n-6 PUFA
Every cooking oils or foods generally include several kinds of fatty acids. Table 3
shows the amounts of different fatty acids in several commercially available oils and
foods. In the US, people use soybean oil very frequently for cooking, and its domi-
nant fatty acid is n-6 PUFA (50%), along with MUFA (25%). Olive oil, a very
popular oil in the Mediterranean Sea area, is a well-known representative with
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MUFA making up more than 70% of all fatty acids. Both soybean oil and olive oil
include SFA at about 15% of all fat. It should be noted that mackerel, which people
believe is a very rich source of fish oil (=n-3 PUFA), contains more than twice as
much SFA and MUFA compared to n-3 PUFA. Bluefin tuna (nonoily tuna) and
salmon contain only one-tenth and one-third the amount of n-3 PUFA compared
with that in mackerel, respectively.
From this table, it is easily understandable that saturated fat is not synonymous
with fat from animal food and likewise unsaturated fat is not synonymous with
plant food. When compared gram for gram, olive oil has 7 times SFA of the trimmed
beef sirloin. Furthermore, the oily fish, mackerel, which are advised to eat, has
more than two times SFA of the beef sirloin. Therefore, it is not unexpected that
results in clinical studies with pharmaceutical drugs with highly purified EPA differ
from those of epidemiological studies with variable fish consumption. When read-
ing manuscripts of nutritional studies with interventions involving fatty acid(s), it
is important to consider which oils or food stuffs are added to modify the specific
fatty acids.
The ratio of n-6 to n-3 fatty acids in the diet of early humans was estimated to be
1:1 [131]. The ratio in the diet of the US today has risen to 10:1 because of the
combination of reduced n-3 fatty acid intake and the widespread use of vegetable
oils rich in linoleic acid (n-6). As shown in Table 3, all listed foods and oils have
much higher content of n-6 compared with that of n-3 except mackerel. It has been
proposed that while n-3 fatty acids have anti-inflammatory effects, n-6 fatty acids
have pro-inflammatory effects. This is based on data that oxylipins synthesized
from n-6 PUFA have more inflammatory, vasoconstrictive, and proliferative effects
compared with a metabolite derived from n-3 PUFA, although there are notable
exceptions [132]. Because enzymes generating inflammatory metabolites from n-6
PUFA are inhibited by EPA and DHA from n-3 PUFA, increases in tissue concen-
tration of EPA and DHA tend to shift the activity toward anti-inflammatory status.
This is the rationale for using the ratio of n-6 to n-3 PUFA (n-6/n-3) in the blood as
a potential risk marker for CV diseases, cancer, and some other chronic inflamma-
tory diseases such rheumatoid arthritis, and bronchial asthma [133]. However, it is
difficult to predict the appropriate cut-off value of n-6/n-3. Furthermore, blood
concentration of n-6/n-3 does not reflect the amount of oral intake of n-3 and n-6
PUFAs [134–136]. At present, a general consensus is that high linoleic acid (n-6
PUFA) in the diet or circulation is not associated with higher in vivo or ex vivo pro-
inflammatory responses, and that those individuals consuming the highest level of
α-linolenic acid (n-3 PUFA) had the lowest inflammatory status [136]. Therefore,
the oral intake of linoleic acid should not be restricted and it is unnecessary to
consume more n-3 PUFAs.
Fat SFA MUFA PUFA n-3 PUFA n-6
Rapeseed oil 100 g 100 g 7.4 g 63 g 9 g 18 g
Soybean oil 100 g 100 g 16 g 23 g 6.8 g 50 g
Olive oil 100 g 100 g 14 g 73 g 0.8 9.8 g
Mackerel 100 g 17 g 4.6 g (27%) 5 g (8.5%) 2.1 g (12%) 0.4 g (2.4%)
Butter 100 g 81 g 51 g (63%) 21 g (26%) 0.3 g (0.3%) 2.2 g (2.7%)
Peanuts 100 g 56 g 11 g (20%) 26 g (46%) 0 g (0%) 17 g (30%)
Figures in parenthesis (%) are the percent of calories from each fatty acid compared to the total amount of fat.
Table 3.
Amounts of different fatty acids contained in several cooking oils, butter and foods.
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Instead of ratio of n-6 to n-3, ω-3 index, based on measurements of EPA and
DHA in red blood cells, was proposed as a marker for previous consumption of fish
for last 120 days [137, 138]. The ω-3 index >8% has been proposed as optimal for
cardioprotection. The average ω-3 index in Japanese is 9–11%. By contrast, the
average in the US people is 4–5% and only <10% of individuals have the ω-3 index
>8% [139], which reflects well the difference of fish consumption between Japan
and the US.
5.2 Epidemiology and history regarding health benefits of fish oil (n-3 PUFAs)
As shown in Table 1, the guidelines from AHA/ACC, ADA, and AACE recom-
mend 2 servings of fatty fish per week for the general population. A typical serving
of fish can range from 3 to 6 ounces (about 85–170 g), depending on the type of fish
and its preparation. Most adult Americans eat only 7–13 g/day of fish, and Japanese
who are 20 years and older eat 73 g/day of fish, based on a 2013 national survey
[140]. Because of the difference of daily intake of fatty food, the percent of calorie
from total fat is higher among Americans than Japanese, except for n-3 PUFA,
which is only 30% higher in Japanese [119, 141]. Reason for the relatively small
difference in fat calorie from n-3 FUFA is that in Americans, the intake of red meat
and poultry as a source of n-3 PUFA is much higher among Americans. When
comparing percent of calories from EPA and DHA between Japanese and Ameri-
cans, this parameter is almost four times higher in Japanese [140, 141]. The percent
of calories from EPA and DHA and their concentration in the blood reflects baseline
consumption of fish intake in diet.
Epidemiological data of Greenlanders from almost half century ago [142] and
WHO study [143] have shown that fish consumption was independently, signifi-
cantly, and inversely associated with all-cause and CHD mortality. In 1999, the
GISSI-P study, the first RCT of dietary supplementation with n-3 fatty acid, showed
significant reduction in the risk of the major CV events by 10% [144]. Based on the
results of this RCT and positive observational studies, since 2000, the European
Medicines Agency (EMA) has authorized n-3 fatty acid medicines for use after a
heart attack in several EU countries, at a dose of 1 g per day. In 2002, the second
AHA Science Advisory “Fish Consumption, Fish Oil, Lipids, and Coronary Heart
Disease” concluded that individuals at risk for CHD benefit from the consumption
of plant- and marine-derived n-3 fatty acids (1 g of EPA + DHA per day) [145].
However, since the 1990s at almost the same time as US and EU recommenda-
tions, conflicting data have been substantially reported showing no correlation
between n-3 fatty acid consumption and CV events [146–154]. The Cochran meta-
analysis in 2004 including 48 RCTs (36,913 participants) and 41 cohort analyses has
concluded that consumption of n-3 fats did not show a reduction in the risk of total
mortality or combined CV events [155]. Until the positive results in the REDUCE-IT
study in 2019 [156], all major RCTs with n-3 fatty acids [157–162] except JELIS
study (Table 4) [163], which were conducted in Japan with open-blind design.
These negative results in observational studies and RCTs were enough to result in
label changes in for n-3 supplements in Europe. In 2016, the ESC/EAS guidelines
concluded that it was unclear whether n-3 fatty acids had beneficial effects on CV
events [39]. Furthermore, 2 years later in 2018, EMA concluded that omega-3 fatty
acid medicines are not effective in preventing further CV events in subjects with a
history of myocardial infarction and that n-3 fatty acid supplements would no
longer be authorized for secondary prevention [164]. Results of the ASCEND study
[162], which was published several months before this recommendation, had sub-
stantially affected this EMA decision. The ASCEND study, which has been the
largest double-blind omega-3 RCT, evaluated MACE for 7.4 years in 15,480 subjects
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Study Year Inclusion Statin Follow up Regimen Baseline TG Primary EP Results
EPA/DHA study
GISSI-P 1999 11,324 Post MI BL = 5% EOS = 46% 3.5 y 850 mg EPA + DHA 162 mg/dl MACE HR = 0.85 (0.74–0.98)
GISSI-HF 2008 6975 HF 22% 3.9 y 850 mg EPA + DHA 126 mg/dl Death + Hosp HR = 0.91 (0.83–0.99)
OMEGA 2010 3851 Post MI 94% 1 y 840 mg EPA + DHA 121 mg/dl Sudden death OR = 0.95 (0.56–1.6)
Alpha-OMEGA 2010 4837 Post MI 85% 3.3 y 400 mg EPA + DHA 144 mg/dl eMACE HR = 1.01 (0.87–1.17)
SU.FOL.OM3 2010 2501 Post MI 85% 4.7 y 600 mg EPA + DHA 115 mg/dl MACE HR = 1.08 (0.79–1.47)
ORIGIN 2012 12,536 dyslipidemia + CVD 53% 6.2 y 840 mg EPA + DHA 140 mg/dl CV death HR = 0.98 (0.87–1.1)
Risk & Prevention 2013 12,513 High risk + CVD 41% 5 y 850 mg EPA + DHA 150 mg/dl CV death HR = 0.97 (0.88–1.08)
ASCEND 2018 15,480 Dm 75% 7.4 y 850 mg EPA + DHA NA MACE HR = 0.9 (0.87–1.08)
Pure EPA study
JELIS 2007 18,645 dyslipidemia 100% 4.6 y 1.8 g EPA 151 mg eMACE HR = 0.81 (0.69–0.95)
REDUCE-IT 2018 8179 CVD+ High risk 100% 4.9 y 4 g EPA 216 mg/dl eMACE HR = 0.74 (0.68–0.83)
DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, BL: baseline, EOS: end of study, EP: end point, MACE: major CV event (death, myocardial infarction, stroke), eMACE: expanded major CV event
(MACE + revascularization).
Table 4.















with diabetes living in England. The n-3 supplements had no effects not only on
CV events but also on mortality of other chronic diseases such as cancer and COPD.
The authors also commented on the issue of cost of n-3 supplements, because up to
31% of all British people were using them. The authors clearly concluded that the
recommendation of n-3 in guidelines in major meetings should be drastically
corrected [162].
Compared with the clear negative opinion against effects of n-3 fatty acids from
EMA, the USFDA has accepted the potential medical benefit of n-3 fatty acids for
secondary prevention. In 2017, the most recent AHA Science Advisory still con-
cluded that treatment with omega-3 PUFA supplements is reasonable for secondary
prevention, stating that a potentially modest reduction in CHD mortality (10%) in
this clinical population would justify treatment with a relatively safe therapy [165].
The Cochran review in 2018 (included 79 RCTs, 112,059 participants) concluded
that increasing n-3 saturated fat intake made little difference to all-cause mortality
and CHD mortality, which did not support the recommendation in the 2017 AHA
Science Advisory of the use of n-3 fat supplements for patients with CHD [166].
Despite the inconsistent recommendation between EMA and FDA, all guidelines
support an indication for reducing TG by n-3 supplements. Furthermore, they
positively advise intake of fish, a rich source of marine- or plant-derived omega-3
fatty acid. The positive effects of fish consumption on CHD have been mostly
attributed to n-3 PUFA (EPA and DHA); however, fish is also an excellent source of
bioactive peptides which have shown beneficial activities for cholesterol-lowering,
hypotensive effects through ACE inhibition, or inhibitory action for atherosclerosis,
inflammation, or oxidation [167]. Supplements containing fish oil are very popular
among people living in the US, being used by 7.8% of the population [168]. The
reason for the popularity of n-3 supplements in the US reflects a typical lifestyle not
to eat fish often (one serving of fish/week) as well as a general belief in beneficial
effects of omega-3 oil for health. The commercially available n-3 supplements do
not contain fish peptides but usually include at least some amount of other ingredi-
ents that are potentially harmful for health such as SFA, mercury, etc.
5.3 Reasons for inconsistent data of omega-3 fatty acids for coronary heart
disease
Most of the RCTs with n-3 supplements generally have not shown a significant
reduction of CV events so far. Table 4 shows comparison of previous RCTs
[144, 156–163, 169]. Inconsistent data in RCTs as well as observational studies of
n-3 supplements could be attributed to statin use, dose of n-3 fatty acid, or TG and
HDL values at baseline. The statin use was very low in two positive studies (GISSI-P
[144] and GISSI-HF [169]), which mainly recruited subjects two decades ago,
before the wide-spread use of stains. One study showed that although among statin-
users coronary vascular events were not reduced with n-3 fatty acid supplements,
the events significantly decreased in statin nonusers [170]. This suggests that statin
treatment modified the effects of n-3 fatty acids on the incidence of major cardio-
vascular events.
The dosage is another important factor. Findings in two Cochran review manu-
scripts showed no dose dependency of n-3 fatty acids [155, 166]. It is of note that the
absolute amount of fish intake was very small in some studies, which tends to make
the correlation between n-3 fatty acids and CV events less clear. In some studies in
cultures where eating fish is not common, the participants who belonged to the
group with the highest intake of fish consumed just 2–3 servings/week, and one
extreme example is a study to compare subjects who consumed no fish to subjects
who ate fish once a week [148]. The JPHC study, conducted in Japan, showed clear
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dose-dependency between n-3 fatty acids and CV events even in the primary
prevention population [171]. Incidence of myocardial infarction was reduced by
56% in the comparison of highest (8 servings per week, or 180 g/day) vs. lowest
quintiles (once a week, or 23 g/day) of fish intake. Generally speaking, a small
gradient of fish consumption is associated with negative results in observational
studies.
Because consumption of omega-3 fatty acids is evaluated based on self-report or
food surveys by questioners, the issue of reliability about how much n-3 fatty acids
was consumed has always existed. Furthermore, variability of n-3 fat content
among fish species makes estimation of EPA + DHA consumption more difficult.
For instance, EPA + DHA ranges from 200 to 300 mg in 3 pounds of wild tuna to
more than 1500 mg in the same amount of wild mackerel.
Dose dependency of n-3 fatty acids appears to be clear in results of RCTs. As
shown in Table 4, whereas doses of EPA/DHA used in recent negative studies were
generally less than 1 g, the JELIS [163] and REDUCE-IT [156] studies, which showed
significant CV risk reduction, used larger doses of EPA (see Sections 4 and 5
REDUCE-IT study). Finally, baseline TG value was suggested to affect the effects of
n-3 supplements. Three positive studies, GISSI-P [144], JELIS [163], and REDUCE-IT
[156] studies recruited subjects with higher baseline TG values of more than 150 mg/
dl compared with the levels in other studies with negative results. In the JELIS study,
whereas 1.8 g EPA reduced CV events in the whole population by 19%, the CV
reduction was 53% in the subgroup with high TG (>150 mg/dl) and low HDL choles-
terol (<40 mg/dl) at baseline [172] (Figure 11). A similar trend toward greater
efficacy in subjects with higher TG and lower HDL-cholesterol at baseline was also
observed in the REDUCE-IT study (Figure 12a and b) [156]. In subjects with high TG
(>200 mg/dl) and low HDL cholesterol (<40 mg/dl) in the REDUCE-IT study, the
percent reduction of primary endpoint by 4 g EPA was almost double (38%) com-
pared with that in subjects with normal TG and HDL-cholesterol (21%, P for interac-
tion = 0.04). In two fibrate studies, the BIP study (bezafibrate) [173] and the
ACCORD study (fenofibrate) [174], no significant reduction of CV events reported
despite the greater decrease in TG (21% in BIP and 26% in ACCORD) with higher
Figure 11.
Kaplan-Meier event curves for the primary end point in the entire cohort (left) and the subgroup with high TG
and low HDL (right) in the JELIS study [163]. The primary end point is a composite of sudden cardiac death,
nonfatal myocardial infarction, nonfatal stroke, unstable angina, and coronary revascularization.
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increases in HDL cholesterol (18% in BIP and 6% in ACCORD) compared with the
REDUCE-IT study (18% decrease in TG and 3% increase in HDL). However, like the
JELIS [163] and REDUCE-IT [156] studies, there was a significant reduction in CV
events in subjects with higher baseline TG at >200 mg/dl [173, 174]. These data
suggest that with greater abnormalities of baseline TG and HDL cholesterol, the two
different dyslipidemic drugs, EPA and fibrates, tend to show greater CV events
reduction. However, from the comparison of efficacy size on CV events in studies
with EPA and fibrates, although at least some of the beneficial effects in the EPA
studies could be explained by changing the plasma lipid, effects other than improve-
ment of dyslipidemia are at work in the reduction of CV events by EPA.
5.4 Antithrombotic effects of n-3 fatty acids
Reduction of CV events by consumption of fish is mostly attributable to benefi-
cial effects of n-3 fatty acids (EPA/DHA). Potential effects include antiplatelet,
activity, inhibition of life-threatening arrhythmia, decrease in LDL cholesterol and
TG, increase in HDL cholesterol, decrease in blood pressure, stabilization of
inflammation in lipid-rich plaque, and antioxidation. Although n-3 fatty acid prod-
ucts are generally approved for TG lowering, this class of drugs has only modest TG
lowering. Based on the modest changes in non-HDL cholesterol, reduction of CV
events is calculated to be only 6–8% [175]. Therefore, changes in lipid profile alone
cannot explain why EPA in the REDUCE-IT study reduced CV events by 25%.
Previous data have indicated that inhibition of platelet aggregation by n-3 fatty
acids at pharmaceutical doses is insufficient for reduction of CV events. Compared
with the reported value of inhibition of platelet aggregation by aspirin, prasugrel, or
ticagrerol, all of which have been proven effective for reduction of CV events,
antiplatelet efficacy of omega-3 fatty acids appears to be relatively small [176].
Supplementation with omega-3 fatty acids had no effect on platelet activation in the
presence of aspirin [177] or clopidogrel [178]. A high level of dietary EPA + DHA
(4.5, 9.5 g) or estimated biologically equivalent amounts of alpha-linolenic acid did
not affect coagulation factors, fibrinogen, plasminogen activator inhibitor-1, or
tissue plasminogen activator activity compared with the control [179]. All of these
data suggest that antithrombotic efficacy via platelets, coagulation, and fibrinolysis
does not play a major role in n-3 fatty acid-induced decrease in CV events in the
positive previous studies.
Figure 12.
(A) Kaplan-Meier event curves for the primary end point in the entire cohort in the REDUCE-IT study [156].
The end point is a composite of CV, nonfatal myocardial infarction, nonfatal stroke, coronary
revascularization, or unstable angina. (B) The hazard ratios and 95% CI in the subgroup according to the
baseline TG and HDL for the primary efficacy end point in REDUCE-IT study [156].
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5.5 REDUCE-IT study
5.5.1 Results of REDUCE-IT study
The REDUCE-IT trial has shown that use of highly purified icosapent ethyl
(EPA) 2 g twice daily reduced CV events by 33% compared with placebo among
patients with high TG and either known CV disease or high risk for CV disease
(Figure 12A) [156]. The absolute reduction of the primary endpoint was 4.8%, and
number needed to treat (NNT) was 21 persons/5 years (105 persons/year). This
number is very excellent compared to other clinical trials recently conducted. There
have been two other positive classes of drugs in addition to statins which showed
significant reduction in CV events, ezetimibe and PCSK9 inhibitor. The absolute
risk reduction in ezetimibe study was only 2% for 7 years (34.7–32.7%) [180]. NNT
was 50 persons/7 years (350 persons/year). In the two PCSK9 inhibitors,
evolocumab [181] and alirocumab [182], NNT value was 67 persons/2.2 years (147
persons/year) and 63 persons/2.8 years (176 persons/year), respectively.
5.5.2 Success factors in the REDUCE-IT study
This study had three distinctive features, compared to the previous n-3 studies that
are considered to be responsible for the positive results; dose, formulation, and baseline
TG. The daily dose of EPA used in the REDUCE-IT study was 4 g, more than four times
higher than the doses used in previous studies. The daily dosage of n-3 supplements is
usually 2 capsules containing the combination of 180mgEPA and 120mgDHA (=0.6 g/
day of n-3), and no more than 2 g/day as dietary n-3 supplements in the FDA recom-
mendation of 2014 [183]. The rationale of 4 g EPA in REDUCE-IT was that the blood
concentration at this dose (183 μg/ml) was similar to that in Japanese subjects in JELIS
studywho received 1.8 g of EPA (170 μg/ml) [156, 185]. This occurred because Japanese
people havemuch higher background intake of fish and thus have higher EPA andDHA
blood concentrations than seen inWestern populations. These data suggest that there
may be some threshold dose to show reduction of CV events despite abundant in vitro
and ex vivo data of various biological effects at smaller doses of n-3 fatty acid.
The entry criteria for TG initially was 150 mg/ml and later was changed to 200 mg/
ml to increase the enrollment of patients with more significant TG elevations. There-
fore, the participants’ TG level at baseline was the highest (TG = 216 mg/dl) among all
omega-3 studies. The ongoing STRENGTH trial, which aims to assess the efficacy and
safety of a 4 g EPA/DHA combination drug, will help to clarify the influence of
different formulations and dosages on CV outcomes. In January 2020, following the
recommendation from DSMB, the sponsor for this study decided to close the Phase III
STRENGTH trial due to its low likelihood of demonstrating a benefit to patients with
mixed dyslipidemia [184]. DHA plus EPA raises LDL levels, whereas EPA alone does
not raise LDL levels. The inclusion criteria for lipids were different in the two studies.
REDUCE-IT had a mineral oil placebo, whereas STRENGTH had a corn oil placebo.
An in vitro study has shown that EPA has direct antioxidant benefits in various apoB-
containing particles that are more pronounced than those of DHA and other TG-
lowering agents [185]. Although all these differences may explain partially the incon-
sistent results in the two studies, it appears most plausible that EPAmay have different
biological effects on CV events compared with those of DHA.
5.5.3 Role of EPA in management of CV disease in the future
The REDUCE-IT study is actually the first study to demonstrate significant
reduction of CV events by purified EPA among Caucasians in the strong statin era.
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Recently, a subgroup analysis of REDUCE-IT study was conducted to determine the
degree of benefit of EPA in the 3146 patients in the United States [186]. As shown in
Figure 13, the US subgroup in REDUCE-IT demonstrated more robust risk reduc-
tion. The primary endpoint was reduced by 31% in the US cohort compared with
20% in the non-US cohort. Especially, whereas total mortality was numerically
increased after 5 years in the non-US cohort, EPA reduced total mortality by 30%
from 9.8 to 7.2% in the US cohort. In the current era when many clinical CV event
trials have failed to show mortality benefit, this magnitude of the decrease in total
mortality in the US cohort is very amazing.
Independent analysis showed that this regimen was a very rare case of high cost-
effectiveness, and that EPA at $4.16/day offered better outcomes at lower health
care costs for payer-eligible patients in the REDUCE IT trial [187]. Cost-
performance results in clinical trials are, generally, very persuasive for obtaining
regulatory approval for FDA and EMA. In December 2019, EPA became the first
FDA approved drug with an indication for reduction of CV risk among patients
with elevated TG levels as an add-on to maximally tolerated statin therapy [188].
A recent analysis of the REDUCE-IT study with the measurement of blood
concentration of EPA has clarified the more important role of pleiotropic effects of
EPA rather than lowering TG as potential mechanisms to reduce CV events [189].
The blood concentration of EPA at baseline was in a relatively narrow range and the
administration of 4 g icosapent ethyl raised the blood levels by 400%. Importantly,
the reduction in CV events seen in the REDUCE-IT trial was directly related to on-
treatment serum levels of EPA [189]. The reduction in TG levels contributed just 2
percentage points to the overall 25 percentage points reduction in CV events in the
study. This means that TG-lowering effect by EPA was not a major reason for the
reduction of CV events in the REDUCE-IT study.
6. Monounsaturated fat
Compared with clinical studies on PUFA, fewer studies focusing on MUFA have
been published in the literature. Whereas the replacement of SFA in the diet with
MUFA increased CV events in some studies [74], other studies showed reduction
[190] or no change [56, 191] in CV events. As already described, one plausible
Figure 13.
The hazard ratios and 95% CI in the US and non-US population for the primary efficacy end point in
REDUCE-IT study [186].
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reason for this inconsistency is the type of MUFA in the studies. It seems clear that
substitution of SFA with olive oil consistently reduced CV events, meaning that it is
necessary to recognize the different metabolic effects between olive oil and other
oils that contain MUFA.
6.1 Lyon Diet Heart study
6.2 Results of the Lyon Diet Heart study
Despite the small decreases in LDL-cholesterol (usually <5%) with the Medi-
terranean diet food, in meta-analysis of many cohort studies, the magnitude of
decreases in CV events was to the same extent or even larger than in statin studies
[192–194]. Effects on CV events beyond LDL-cholesterol reduction with the Medi-
terranean diet has been demonstrated in two RCTs, the Lyon Diet Heart study and
the PREDIMED study [6]. The Lyon Diet Heart study [82, 195], which was the first
RCT of the Mediterranean diet before the statin era, randomized 605 patients with
history of myocardial infarction to compare that diet with a French style diet. The
Mediterranean diet reduced the primary endpoint by 73% (CI: 0.12–0.59,
P = 0.001). The overall mortality was also reduced by 70% (CI: 0.11–0.82, P = 0.02).
Although the study was originally planned to follow CV events for 5 years, it was
terminated early, 2 years and 3 months after the study initiation, due to the high
mortality rate in the control group. There were no significant differences in body
weight, blood pressure, LDL and HDL cholesterol, and blood glucose levels between
the two diet groups at the end of the study. Therefore, the marked differences in
rates of CV events were not due to improvement of these classical surrogate risk
markers. The investigators presented results of an extended follow-up, and the
striking reduction of CV evens was maintained for up to 4 years [195].
6.2.1 Nutritional data in the intervention and control group
Table 5 shows the comparison of nutritional data in the intervention and control
groups at the end of the study (27 months after the randomization) [82, 195, 196].
Control Intervention P To maintain desirable BW
Step 1 Step 2
Energy, cal 2088 1947 0.033
Total lipids, E% 33.6 30.4 0.002 <30 <30
SFA, E% 11.7 8.0 0.0001 8–10 <7
PUFA, E% 6.1 4.6 0.0001 up to 10
Linolenic (n-3), E% 0.29 0.84 0.0001
Linoleic (n-6), E% 5.3 3.6 0.0001
Oleic (MUFA), E% 10.8 12.9 0.0001 up to 15
Carbohydrate, E% 49.8 53.4 N/A
Protein, E% 16.6 16.2 0.3
Fiber, g 15.5 18.6 0.004 20–30
Cholesterol, mg 312 203 0.0001 <300 <200
Table 5.
Comparison of nutritional data in the intervention and control groups in the Lyon Diet Heart study at the end
of the study (27 months after the randomization) [82, 195, 196].
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In order to show the uniqueness of the intervention group in this Lyon Diet Heart
study, the nutrient profiles of the NECP/AHA step 1 and step 2 are also presented.
Because the intake of calories and the percentages of energy (E%) of three major
nutrients were relatively similar, it appears that the differences in fat components
had substantial effects on CV events. In the Mediterranean diet group, SFA was 32%
lower (8.0 vs. 11.7%), oleic acid (MUFA) was 20% higher (12.9 vs. 10.8%), and α-
linolenic acid (n-3 PUFA) was 190% higher (0.84 vs. 0.29%). Because there was no
restriction of butter, fatty red meat, or snacks (rich sources of SFA) in the control
diet group, and animal meat has also high content of MUFA, the energy percentage
of SFA was high in the control diet group and the total unsaturated fat (MUFA +
PUFA) was not different between the two groups (control vs. Mediterranean: 16.9
vs. 17.5%). The change in fat components in the Mediterranean diet group was not
in accord with the current general recommendations regarding SFA and PUFA. The
group had relatively high intake of SFA (8%) and lower intake of PUFA than in the
control group (4.6 vs. 6.1%, Table 4), which could explain the small change in LDL
cholesterol by the intervention. The findings in this study clearly illustrate the
importance of the risk factors beyond lipids and lipoproteins.
Compared with data in PREDIMED study [6], conducted two decades later,
which was loaded with extra-virgin olive oil and nuts with less refined carbohy-
drate, the percentage of energy of MUFA was almost half (12.9 vs. 22.1%), fat
calorie was 10.8% lower (30.4 vs. 41.2%), and inversely, carbohydrate calories were
12.2% higher in the Mediterranean diet group in the Lyon Diet study (53.4 vs.
41.2%). Furthermore, the percent of calories from n-3 PUFA was low compared
with those values in the REDUCE-IT [156] and JELIS [163] studies where highly
purified marine-derived n-3 EPA was given. Therefore, it is unlikely that the bene-
ficial, biological effects of n-3 PUFA or MUFA on CV risk reduction were maxi-
mally utilized for the reduction of CV events in the Lyon Diet Heart study. The very
high value of SFA in the control group (11.7%) may be another factor contributing
the exaggerated CV event reduction in this study. In one cohort study with 2.96
million person-years of follow-up which evaluated effects of red meat consumption
on risk of CV diseases [197], the total mortality in the top quintile was 40% higher
than in the bottom quintile. SFA consumption in the control group in the Lyon Diet
Heart study was almost identical to that in the top quintile in that cohort study. At
present, as SFA is well known to increase in LDL cholesterol, it is nearly impossible
to conduct any diet trials with more than 8% intake of SFA for ethical reasons.
6.3 PREDIMED study
6.4 Protocol and results
The second RCT of the Mediterranean diet was the PREDIMED study [6]. There
are several distinctions between the Lyon Diet Heart and PREDIMED studies. First,
the PREDIMED study had much more participants (605 vs. 7447 subjects). Second,
the Lyon Diet Heart study enrolled subjects with a history of acute myocardial
infarction, and by contrast, the target is primary prevention with a high CVD risk in
the PREDIMED study. Third, the Mediterranean diets were substantially different
in the two studies. In the Lyon Diet Heart study, the Mediterranean diet was
enriched with alpha-linolenic acid (n-3 PUFA), because margarine was provided
freely in substitution for butter and cream, but not olive oil, and, by contrast, in the
PREDIMED study, the diet for participants assigned to be the Mediterranean groups
was loaded with extra-virgin olive oil or nuts. Finally, regarding the fat content in
the control group diet, a high-fat diet was used in the Lyon Diet Heart and a low-fat
diet in the PREDIMED study.
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After the original version of the PREDIMED study was protocol was published
in 1993 [198], statistical issues and randomization errors had been corrected, and
then a revised version was published in 2018 [6]. Participants were randomized into
one of three interventions: Mediterranean diet supplemented with extra-virgin
olive oil (EVOO, a minimum of 50 ml/day for participants), or Mediterranean diet
supplemented with nuts (30 g/day: 15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts)
or control diet (advice to follow a low-fat diet). The reasons for recommending
EVOO was that the content of polyphenol is quite variable among olive oils, and
that EVOO has reduced CV events to a greater extent compared with non-EVOO
(HR 0.84 vs. 0.97) [199]. All participants were Spanish people living in the Medi-
terranean area. Olive oil is a rich source of MUFA (usually more than 70% of all fat)
as well as phenolic antioxidants. Walnuts contain much more PUFA (n-3: 14%, n-6:
58%) than MUFA (14%) compared with EVOO (PUFA: 13%, MUFA: 70% or more).
The other half of the nut allowance was almonds and hazelnuts, both rich in MUFA
(80%) and polyphenols. Thus, although having the same general food pattern as the
Mediterranean diet, the EVOO group was enriched in MUFA and polyphenols and
the nuts group was enriched in MUFA and (n-3, n-6) PUFA as well as polyphenols.
Figure 14 shows the daily intake of EVOO and nuts in the three groups in the
PREDIMED study compared with that of Japanese aged of >60 y/o in 2015. Con-
sumption of EVOO and nuts was very high in subjects who followed the Mediter-
ranean diet with EVOO or nuts, respectively. It is noteworthy that even the control
group had much higher consumption of EVOO than in Japanese (data on average
consumption is not available; however, based on amounts of import and domestic
production of olive oil in Japan, this value is very likely to be in the low single digits)
and in the US population (4.2 g/day/person) [79]. Consumption of nuts was also
high in the two Mediterranean groups and substantially higher in the control low-
fat group than in Japanese, and probably in Americans, because according to statis-
tical data in a US national survey in 2009–2010, 63.3% of men and 60.5% of women
in the US did not consume any nuts on a given day [200]. These data indicate that
all participants including those in the control cohort in this study had, to some
extent, Mediterranean-style diet.
The primary endpoint (MI, stroke, and CV death) was significantly reduced,
with an adjusted hazard ratio of 0.69 (CI, 0.53–0.91) for the EVOO group and 0.72
(9CI, 0.54–0.95) for the nuts group, as compared with the control diet (Figure 2).
The Kaplan-Meier curves for the primary end point diverged soon after the trial
started. The average age of participants in this study was 67 years old and a sub-
group analysis showed that CV events were reduced by 30% in people more than
70 years old, similar to the value in younger people, indicating that it is never too
Figure 14.
Daily consumption of olive oil and nuts in the PREDIMED study at the end of the study compared with those in
Japanese in their 60s [6, 140].
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late to change dietary habits to improve CV health. It should be stressed that the two
Mediterranean diets decreased systolic blood pressure by 5–6 mmHg, LDL- choles-
terol by 5% or less, and fasting blood glucose by 2–4 md/dl, and that these small
changes of risk factors alone can hardly explain the very early and significant 30%
risk reduction of the primary end point.
6.4.1 Comparison to other CV studies to intervene in traditional CV risk factors
Although the primary end point was positive in the entire cohort of subjects
including those in primary and secondary prevention studies, of the CANVAS
program (canagliflozin) [201], the DECLARE-TIMI58 study (dapagliflozin) [202],
or the LEADER study (liraglutide) [203], the subgroup analyses have shown a very
small reduction in primary endpoint in subjects without established atherosclerotic
diseases (Figure 15).
The absolute and relative risk reduction by aspirin was 0.06%/year and 12% in
primary prevention group [204] and thus, because of increased bleeding complica-
tions, aspirin has not been indicated in subjects without CV diseases. What is
remarkable in the PREDIMED study is that the huge reduction in CV events was
Figure 15.
The hazard ratios and 95% CI in the PREDIMED, CANVAS, DECLARE, and LEADER studies according to
presence or absence of established CV diseases [6, 201–203].
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observed in the primary prevention cohort (Figure 15), where rates of CV events
are usually low and historically, effects of drugs are rarely observed in pharmaco-
logical trials. The absolute risk reduction was almost five times higher in the
PREDIMED study (0.32%/year) than that of aspirin (0.06%/year) [204].
The rapid onset of reduction in CV events should also be addressed. Figure 16a
and b shows the Kaplan-Myers curves of the Lyon Diet Heart, PREDIMED,
dyslipidemia (CARE [205] and ODESSEY OUTCOME [181]), hypertension
(ADVANCE [206] and SPRINT [207]), and diabetes (CANVAS program [201] and
LEADER [203]) studies. Whereas it takes 6 months to 2 years before the decline in
CV events in most of these studies, the Kaplan-Myer curves of the two Mediterra-
nean diet studies were separated early in the course, less than half a year. Previous
studies have shown that it takes years for imaging parameters to significantly
change during antihypertensive agents with carotid ultrasound [208], statin ther-
apy [209] or an antidiabetic drug [210] with coronary intravascular ultrasound
(IVUS). Considering that process in regression of plaque size needs years from
studies with these image modalities, the Mediterranean diet in the PREDIMED
study may be associated with early changes in plaque component, causing more
stable atherosclerotic plaque which results in reduction of CV events.
6.4.2 Comparison of macronutrients between groups in PREDIMED study
Figure 17 shows comparison of total calories and percent energy from protein,
fat, and carbohydrate (Figure 17a), and percent energy from each fatty acids
(Figure 17b) in the PREDIMED study at the end of the study. For comparison with
residents in non-Mediterranean diet cultures, data for Japanese in their 60s in 2015
[140] and US adults at age > 60 years old (total calories) and >20 years old (3 major
nutrients) in 2011 [120] are also shown. In the two Mediterranean diet groups, high
fat food was allowed, as long as the fat was derived from vegetable sources, partic-
ularly olive oils and nuts, and also from fatty fish. As a result, the total calories
reached approximately 2200 kcal/day with fat calories exceeding more than 40% of
total calories, and both of them were higher than in the low-fat control diet group
(1960 kcal/day and 37%). Clearly, this was a calorie-unrestricted, high-fat diet,
which is usually not recommend in obese subjects.
Figure 16.
(a) Kaplan-Meier event curves for the primary end point in the Lyon Diet Heart, PREDIMED, CARE, and
ODYSSEY OUTCOMES studies [6, 201–203]. (b) Kaplan-Meier event curves for the primary end point in the
ADVANCE, SPRINT, CANVAS, and LEADER studies [201, 203, 206, 207].
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Figure 17.
(a) Total calories and percent energy from protein, fat, and carbohydrate in the PREDIMED study at the end of
study [6] compared with those of Japanese in their 60s in 2015 [140] and those of US adults at age > 60 years
old (total calories) and >20 years old (protein, fat, and carbohydrate) in 2011 [120]. (b) Percent energy from
SFA, MUFA, and PUFA in the PREDIMED study at the end of the study compared with those of Japanese in
their 60s in 2015 [140] and those of US adults at age > 20 years old in 2011 [120].
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Average BMI of participants at baseline was approximately 30 and half of them
fell within the class 1 obesity category (BMI > 30). A calorie-restricted diet with
limited fat consumption (<30–35% of calories as fat) is usually recommended for
these subjects. In the control diet group, although the focus was to reduce all types
of fat and they were advised to avoid fatty foods, fat calories was elevated at 37%.
This value is actually higher than in the standard low-fat diet (<30%), and higher
than in Japanese and even the US adults. Therefore, all participants in the
PREDIMED study represent people receiving a high fat diet. Regarding carbohy-
drates, in the control group, low-fat dairy products, refined carbohydrates, fruits,
and vegetables were recommended as substitution for high-fat foods Therefore, a
decrease in fat calories in the control group was compensated with an increase in
carbohydrate calories, which was higher than the two Mediterranean diet groups.
However, the level of carbohydrate calories in the control group was still lower than
in Japanese and US adults.
Percent calories from fat type after 5 years of treatment in the PREDIMED study
deserve attention (Figure 17b). The participants of all three groups were to restrict
intake of red and processed meat, commercial bakery goods, sweets, and pastries,
all of which are abundant sources of SFA, and were advised to select white meats
(poultry without skin or rabbit). However, white meat contains a high content of
SFA (30–40% of all fat). Olive oil (15%) and nuts (40% in walnuts, 7% in hazelnuts
and peanuts) also contain significant amounts of SFA. As a result, the SFA was
equally increased to 9% in each group, which is beyond the recommended level of
SFA (<7%) in authoritative opinions. The percent SFA calories in the participants
in the PREDIMED study was higher than in Japanese (in their 60s) and less than in
US adults (>20 y/o).
Because of increased consumption of EVOO or nuts, MUFA was substantially
higher in the EVOO and nuts group (22.1, 20.9 vs. 18.8% in control group) than in
the control group. Compared with intake of MUFA in Japan (9.6%) and the US
(13%), the very high percent of calories from MUFA is the most distinctive feature
that characterizes the changes in nutrition in the two intervention groups. The daily
recommend dose of MUFA is not defined in many guidelines except the AACE 2017
guideline which defines it as less than 10% of calories. Even in the control group,
the percent of calories from MUFA (18.8%) was much higher than in subjects
assigned to the Mediterranean diet in the Lyon Heart Diet study (12.9%) [82, 195].
This is because, in addition to daily intake of olive oil and nuts, many foods in
Mediterranean diets are rich in MUFA, and are lower in SFA. The percent energy of
PUFA was similar between the three groups and was not very different from in
Japan and US. Furthermore, because the consumption of important food compo-
nents for Mediterranean diet, such as fish, fruits, and vegetables (Figure 18), was
maintained at high levels during the course of the study, the compliance in diet as
described in the protocol was excellent in most participants in the PREDIMED
study.
6.4.3 Potential mechanisms of reduction of CV events by olive oil and nuts
The Mediterranean diet protects against CV disease via numerous mechanisms,
including reduction of blood pressure, LDL cholesterol, and blood glucose,
improvement of vascular endothelium, vasodilation, anticoagulation, anti-
inflammation, and antioxidant activity [192, 211]. Although components of the
Mediterranean diet, which consists of fish, olive oil, vegetables, fruits, whole grains,
legumes/nuts, and moderate red wine consumption, have been found to reduce CV
disease risk, the general consensus is that a Mediterranean diet offers benefit against
CV disease in aggregate rather than considering the effects of individual
32
New Insights into Metabolic Syndrome
constituents [211, 212]. This is further supported by data that the reduction of CV
disease is correlated with rating for overall adherence of the Mediterranean diet
[193, 213, 214]. The control group in the PREDIMED study did not consume a
typical low-fat diet but rather a Mediterranean diet with mild restriction of olive oil
or nuts. The subjects in the control group consumed food constituents affecting CV
disease risk such as fish, vegetables, and fruits to the similar extent as in the
Mediterranean diet groups except for EVOO and nuts (Figures 14 and 18). These
findings indicate that, contrary to the previous concept of beneficial effects by
synergy of all nutrients in the Mediterranean diet, extra-loaded EVOO and nuts
play a critical role in the reduction of CV events in the PREDIMED study.
The key message in the PREDIMED study is that only adding EVOO or nuts to
calorie-unrestricted Mediterranean diet has cut CV events by approximately 30%.
High-sensitive CRP (hsCRP) in blood reflects systemic vascular inflammation. In
the PROVE-IT study, 80 mg atorvastatin decreased hsCRP by 36% along with
reduction of CV events by 16% [215]. In the PREDIMED study, hsCRP decreased by
50 and 40% in the EVOO and nuts groups compared with the control group
[6, 198]. The magnitude of changes in hsCRP and CV events were numerically
greater in the PREDIMED study than in the stain trials. These data indicate that the
diet interventions have resulted in substantial improvement of vascular inflamma-
tion resulting in 30% CV event reduction. The mechanism(s) responsible for stabi-
lization of vascular inflammation with the Mediterranean diet remains still unclear.
How about the magnitude of the well-known antioxidant effects of EVOO and
nuts in the two Mediterranean diet intervention groups? The difference in amounts
of polyphenol, a representative antioxidant in EVOO and nuts in the intervention
groups vs. the control group, is estimated to be around 10 mg/day. Polyphenol is
very abundant in other foods, such as red wine (200–400 mg/100 ml), beans (500–
Figure 18.
Daily consumption of fish, meat, fruit, and vegetable in the PREDIMED study at the end of the study compared
with those of Japanese in their 60s in 2015 [140] and those of US adults at age > 20 years old in 2011 [120].
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1500 mg/100 g), vegetables, and fruits, and more than 1000 mg/day is usually
consumed in a typical dinner on the Mediterranean diet. Furthermore, although
laboratory experiments have shown beneficial effects of many antioxidants (vita-
min A, C, E, NAC, polyphenol) on vascular atherosclerosis, results of human stud-
ies have generally been negative [216]. All of these data strongly suggest that the
anti-oxidant effects of EVOO or nuts alone is unlikely to explain reduction in CV
events observed in the two Mediterranean diet groups in the PREDIMED study.
In human, two cohort studies have shown that there was an inverse association
between the dose of olive oil and CV risk [199, 217]. In the EPIC-Spain cohort study,
the highest quartile of olive oil consumption (>30 g/day) was associated with a 26%
reduction in risk of overall mortality and a 44% reduction in CVD mortality in
comparison with non-consumers. For each increase of 10 g/day in olive oil, there
was a 7% decreased risk of overall mortality and a 13% decreased risk of CVD
mortality. In the PREDIMED study, the highest tertile group of mean intake of total
EVOO (56.9 g/day) showed 48% reduced risk of CV mortality compared with those
of the lowest tertile (21.4 g) [78]. As in previous study [21], for each 10 g/day
increase in EVOO consumption, CV disease and mortality risk decreased by 10 and
7%, respectively, in the PREDIMED study. Results of all these data suggest that
more CV benefit is expected for higher intake of EVOO up to 30–60 g/day.
In contrast to olive oil, the beneficial effects of nut consumption on CV disease
were not consistently shown in three recent meta-analyses [218–220], whereas
significant reduction in LDL cholesterol, and inflammatory and oxidants mediators
were consistently reported with nuts consumption. It is important to note that the
amount of walnuts consumed in previous trials was relatively large (30–108 g/day),
representing 5–25% of total calories. This level of consumption appears to be diffi-
cult to maintain in a non-research setting. Recommended daily dose of nuts
according to FDA is one ounce (28 g). The average nut consumption was 30 g/day
in the nuts group in the PREDIMED study [6, 198]. For the first time, the
PREDIMED study clearly showed that relatively small amount of nuts (30 g/day,
about 180 kcal) is enough to reduce CV events.
6.4.4 Effects of olive oil in the US population and the PREDIMED-PLUS study
Although the results of the PREDIMED study have highlighted effects of olive
oil and nuts, it is of note that CV benefits of olive oil and nuts were seen in
conjunction with the other components of the Mediterranean diet. It still remains
unclear what are the biological effects of EVOO and nuts that underlie the reduction
of CV events. What is more important practically is whether similar effects on
reduction in CV events is reproduced with supplements of EVOO and nuts on other
types of diets, or whether lower amounts of EVOO and nuts have similar CV benefit
as seen in the PREDIMED study.
All the previous studies in this area have been conducted in Mediterranean
countries. The effects of olive oil on CV risk have not yet been evaluated in the U.S.
population. As shown in Figure 18, the consumption of fish, fruit, and vegetables
for the US population, important components in Mediterranean-style diet, is in the
rage of 25–50% compared with that the participants in the PREDIMED study.
Conversely, the consumption of meat for the US population is more than double.
The critical question is whether olive oil or nuts can exhibit beneficial effects on CV
risk on the background of the western style diet similarly as they have in previous
observational, cohort, and RCTs of the Mediterranean diet. The recent pooled
analysis from 61,181 women from the Nurses’ Health Study and 31,797 men from
the Health Professionals Follow-up Study has shown some answer for this
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important question [79]. Replacing about 1 teaspoon per day (5 g/day) of marga-
rine, butter, or mayonnaise, or daily fat with an equivalent amount of olive oil was
associated with a 5–7% lower risk for total CV disease. When olive oil was compared
with other plant-derived oils, there were no significant associations. Mean intake in
the group using the highest amount of olive oil was 12 g/day in this study, not as
high as in the Spanish participants of the PREDIMED study at 50 g/day. This study
has provided further support for the recommendation to replace saturated fat from
animal fat with plant oils, such as olive oil, that contain more MUFA for the
prevention of CV disease in the general population in the US.
The protocol of the PREDIMED study did not restrict total calorie intake and did
not recommend any exercise therapy. Therefore, it was criticized as showing very
small beneficial effects on body weight. Although the two Mediterranean diet
groups consumed 200–270 kcal more, the incidence of new diabetes was reduced
about 50% compared with the control group (10.1, 11 vs. 17.9%, EVOO, nuts vs.
control) [221]. If the participants in the PREDIMED study could have received
calorie-restricted diet with optimal exercise therapy, then this could have resulted
in fewer incidence of new patients with diabetes.
Currently another study, the PREDIMED-PLUS study, a 6-year, multicenter,
randomized clinical trial for the primary prevention of CVD is ongoing [222]. The
objectives of this study is to compare an energy-restricted Mediterranean diet plus
advice to increase physical activities with a control, energy-unrestricted Mediterra-
nean diet without counseling on physical activities in 6874 older individuals (www.
isrctn.com/ISRCTN 89898870). The energy-reduced Mediterranean diet features
more restrictive limits for red and processed meats, butter, and carbonated sweet-
ened drinks than an unrestricted Mediterranean diet. Although this is definitely the
optimal treatment for overweight or obese individuals, the major challenge is par-
ticipant adherence. However, initial results from a pilot study in 626 participants
showed better adherence of the energy-reduced Mediterranean group [223]. This
study is expected to result in more reduction in CV events with further fine-tuning
of the Mediterranean diet in the future.
7. Final remarks
The two Mediterranean diet intervention studies, the Lyon Heart Diet and
PREDIMED studies, have reduced CV events by 72 and 30%, respectively. The
magnitude of efficacy of these results are more powerful compared with those in
statin trials. CV specialists usually lack the nutrition education to effectively imple-
ment diet therapy. In the current era of a shift from disease treatment toward
prevention, how can we maintain our knowledge for updated nutritional science to
provide best diet therapy to patients? Characteristics of diet therapy should be
simple, understandable, and long lasting for many subjects. For this purpose, phy-
sicians must keep studying nutritional science, and should be practicing healthy diet
life by themselves. A recent study using an online survey has shown that only 20%
of cardiologists eat 5 servings of vegetables and fruits per day [3]. Consuming
healthy food by themselves will help to more confidently and comfortably recom-
mend appropriate diet therapy to their patients. In contrast to evidence levels in
pharmacological therapy, there have been few trustworthy RCTs in nutrition,
which thus has created substantial inconsistent understanding of diet therapy at
present. In the future, it is by far the most important task for related parties to be
united to build up a foundation of high quality data of nutritional science.
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